Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Journey Medical Corporation (DERM)

5.17 -0.24 (-4.44%)
At close: October 30 at 4:00:00 PM EDT
5.20 +0.03 (+0.58%)
After hours: October 30 at 4:00:09 PM EDT
Trade DERM on Coinbase
Chart Range Bar
Loading chart for DERM
  • Previous Close 5.41
  • Open 5.36
  • Bid 3.76 x 200
  • Ask 6.55 x 200
  • Day's Range 5.10 - 5.36
  • 52 Week Range 4.31 - 9.56
  • Volume 235,057
  • Avg. Volume 199,984
  • Market Cap (intraday) 145.92M
  • Beta (5Y Monthly) 1.11
  • PE Ratio (TTM) --
  • EPS (TTM) -0.22
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 13.75
  • Motley Fool Rating Bearish

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

journeymedicalcorp.com

58

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DERM
32.94%
S&P 500 (^GSPC)
10.73%

1-Year Return

DERM
37.79%
S&P 500 (^GSPC)
11.11%

3-Year Return

DERM
61.56%
S&P 500 (^GSPC)
81.91%

5-Year Return

DERM
40.57%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 18.51M
Earnings -312k
Profit Margin -1.69%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5M
10M
15M
-12.0%
-10.0%
-8.0%
-6.0%
-4.0%
-2.0%

Analyst Insights

View More

Analyst Price Targets

13.00
13.75 Average
5.17 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/26/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 13 -> 13

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    146.20M

  • Enterprise Value

    146.10M

  • Trailing P/E

    --

  • Forward P/E

    20.72

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    2.03

  • Price/Book (mrq)

    4.46

  • Enterprise Value/Revenue

    2.14

  • Enterprise Value/EBITDA

    114.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.95%

  • Return on Assets (ttm)

    -2.10%

  • Return on Equity (ttm)

    -23.77%

  • Revenue (ttm)

    68.18M

  • Net Income Avi to Common (ttm)

    -6.1M

  • Diluted EPS (ttm)

    -0.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    25.64M

  • Total Debt/Equity (mrq)

    79.53%

  • Levered Free Cash Flow (ttm)

    -5.46M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.17 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 03/26/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 10/18/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 09/11/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: